• English
  • Svenska
  • Clinical Utility

AroCell targets in vitro diagnostic applications and in particular monitoring the effectiveness of treatment of cancer from a simple blood test. In cancer, time is everything. AroCell TK 210 ELISA can also provide useful information in drug discovery and development using Thymidine Kinase 1 as biomarker.

DRUG DISCOVERY AND DEVELOPMENT

Measurement of proliferation, or progression and remission of tumor growth is in the drug discovery. AroCell TK 210 ELISA, opens the opportunity to monitor the efficacy and dose response of drug candidates in drug discovery.

Read more

PRECISION MONITORING IN CANCER CARE

How do cancer patients respond to treatment? TK1 as biomarker in cancer care can help clinicians make timely and decisions about ongoing treatment of every patient.

Read more

BREAST CANCER

Breast cancer is the most common cancer in women worldwide. There is a need for new biomarkers to measure the effectiveness of treatment. TK1 is a strong candidate, and samples can be collected easily by a simple blood sample.

Read more

HEMATOLOGICAL MALIGNANCIES

TYK1 has been used substantially in clinical studies of hematological malignancies. Preliminary studies show that AroCell TK 210 ELISA can be used to predict outcome and monitor effectiveness of drug treatment of DLBCL, the most common non-Hodgkin’s Lymphoma.

Read more

OTHER SOLID TUMORS

Tumors are oncology malignancies that form a discrete tumor mass in, for example, the breast, prostate, kidney, ovary, esophagus, and lung. There is a clinical need to monitor the effect of the therapy to optimize the management of the disease in many cancers. AroCell is selectively exploring the role of TK1 as biomarker in solid tumors.

Read more

CLINICAL STUDIES

AroCell is participating in several clinical studies, both with partners and independently.

 

 

 

Read more

Subscription for news and press releases

We use cookies to improve the user experience and gather anonymous visitor statistics. By using our website, you agree to the use of cookies.

I agree.